Comparative structural studies on Lys49-phospholipases A2 from Bothrops genus reveal their myotoxic site

Journal of Structural Biology

Volumn 167, Issue 2, 2009, Pages 106-116

  dos Santos, Juliana I ^a   Soares, Andreimar Martins ^b   Fontes, Marcos R M ^a  

^a SÃO PAULO STATE UNIVERSITY UNESP   (Brazil)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Tocopherol; Bothrops genus; Homologue phospholipase A2 assembly; Myotoxicity; Phospholipase A2; X ray crystallography

Indexed keywords

ALPHA TOCOPHEROL; ARGININE; LYSINE; PHOSPHOLIPASE A2; SNAKE VENOM;

ARTICLE; CARBOXY TERMINAL SEQUENCE; COMPARATIVE STUDY; CONTROLLED STUDY; ENZYME ANALYSIS; ENZYME CONFORMATION; ENZYME STRUCTURE; MUSCLE DISEASE; MUSCLE TOXICITY; NONHUMAN; PRIORITY JOURNAL; SEQUENCE ALIGNMENT; SNAKE; STRUCTURE ANALYSIS; TOXIN ANALYSIS; X RAY CRYSTALLOGRAPHY;

ANIMALS; BOTHROPS; CATALYTIC DOMAIN; CROTALID VENOMS; CRYSTALLOGRAPHY, X-RAY; GROUP II PHOSPHOLIPASES A2; LIGANDS; PHOSPHOLIPASES A; PROTEIN CONFORMATION; PROTEIN MULTIMERIZATION; REPTILIAN PROTEINS;

BOTHROPS;

EID: 67650001629     PISSN: 10478477     EISSN: 10958657     Source Type: Journal    
DOI: 10.1016/j.jsb.2009.04.003     Document Type: Article

References (72)

1. Abate A., Yang G., Dennery P.A., Oberle S., and Schroder H. Synergistic inhibition of cyclooxygenase-2 expression by vitamin E and aspirin. Free Rad. Biol. Med. 29 (2000) 1135-1142
2. Ambrosio A.L.B., Nonato M.C., Selistre-de-Araújo H.S., Arni K., Ward R.J., Ownby C.H., de-Souza D.H.F., and Garratt R.C. A molecular mechanism for Lys49-phospholipase A2 activity based on ligand-induced conformational change. J. Biol. Chem. 280 (2005) 7326-7335
3. 2 from Bothrops jararacussu snake venom. Biochem. Pharmacol. 64 (2002) 723-732
4. Angulo Y., Gutiérrez J.M., Soares A.M., Cho W., and Lomonte B. Myotoxic and citolytic activities of dimeric Lys49 phospholipase A2 homologues are reduced, but not abolished, by a pH-induced dissociation. Toxicon 46 (2005) 291-296
5. 2-a structural review. Toxicon 34 (1996) 827-841
6. Arni R.K., Ward R.J., Gutiérrez J.M., and Tulinsky A. Structure of a calcium-independent phospholipase-like myotoxic protein from Bothrops asper venom. Acta Crystallogr. D Biol. Crystallogr. 51 (1995) 311-317
7. 2 homologue isolated from the venom of Cerrophidion (Bothrops) godmani. Arch. Biochem. Biophys. 366 (1999) 177-182
8. Austin A.C., and Funk C.D. Insight into prostaglandin, leukotriene, and other eicosanoid functions using mice with targeted gene disruptions. Prostaglandins Other Lipid. Mediat. 58 (1999) 231-252
9. 2: insight from the anion-assisted dimer. Arch. Biochem. Biophys. 433 (2005) 96-106
10. Balsinde J., Balboa M.A., Insel P.A., and Dennis E.A. Regulation and inhibition of phospholipases A2. Annu. Rev. Pharmacol. Toxicol. 39 (1999) 175-189
11. Beers S.A., Buckland A.G., Koduri R.S., Cho W., Gelb M.H., and Wilton D.C. The antibacterial properties of secreted phospholipases A2. A major physiological role for the group IIA enzyme that depends on the very high pI of the enzyme to allow penetration of the bacterial cell wall. J. Biol. Chem. 277 (2002) 1788-1793
12. Berk P.D., and Stump D.D. Mechanisms of cellular uptake of long chain free fatty acids. Mol. Cell Biochem. 192 (1963) 17-31
13. Bingham III C.O., and Austen K.F. Phospholipase A2 enzymes in eicosanoid generation. Proc. Assoc. Am. Physicians 111 (1999) 516-524
14. Bon C., Changeux J.O., Jeng T.W., and Fraenkel-Conrat H. Postsynaptic effects of Crotoxin and its isolated subunits. Eur. J. Biochem. 99 (1979) 471-481
15. Brünger A.T., Adams P.D., Clore G.M., Delano W.L., Gros P., Grosse-Kunstleve R.W., Jiang J.S., Kuszewski J., Nilges M., Pannu N.S., Read R.J., Rice L.M., Simonson T., and Warren G.L. Crystallography and NMR system: a new software suite for macromolecular structure determination. Acta Crystallogr. D Biol. Crystallogr. 54 (1998) 905-921
16. Chandra V., Jasti J., Kaur P., Betzel C., Srinivasan A., and Singh T.P. First structural evidence of a specific inhibition os phospholipase A2 by α-tocopherol (vitamin E) and its implications in inflammation: crystal structure of the complex formed between phospholipase A2 and α-tocopherol at 1.8 Å resolution. J. Mol. Biol. 320 (2002) 215-222
17. Chang C.C., Lee J.D., Eaker D., and Fohlman J. Short communications the presynaptic neuromuscular blocking action of taipoxin. A comparison with p-bungarotoxin and crotoxin. Toxicon 15 (1977) 571-576
18. Chioato L., de Oliveira A.H., Ruller R., Sá J.M., and Ward R.J. Distinct sites for myotoxic and membrane-damaging activities in the C-terminal region of a Lys49-phospholipase A2. Biochem. J. 366 (2002) 971-976
19. Chioato L., Aragão E.A., Ferreira T.L., Medeiros A.I., Faccioli L.H., and Ward R.J. Mapping the structural determinants of artificial and biological membrane damaging activities of a Lys49 phospholipase A2 by scanning alanine mutagenesis. Biochim. Biophys. Acta 1768 (2007) 1247-1257
20. Corrêa L.C., Marchi-Salvador D.P., Cintra A.C., Sampaio S.V., Soares A.M., and Fontes M.R.M. Crystal structure of a myotoxic Asp49-phospholipase A2 with low catalytic activity: insights into Ca(2+)-independent catalytic mechanism. Biochim. Biophys. Acta 1784 (2008) 591-599
21. 2 homologue. Proteins 30 (1998) 442-454
22. 2-homologue from Bothrops pirajai venom. Toxicon 36 (1998) 1395-1406
23. de Azevedo Jr. W.F., Ward R.J., Gutiérrez J.M., and Arni R.K. Structure of a Lys49-phospholipase A2 homologue isolated from the venom of Bothrops nummifer (jumping viper). Toxicon 37 (1999) 371-384
24. DeLano W.L. The PyMOL Molecular Graphics System (2002), DeLano Scientific LLC, San Carlos, CA, USA
25. dos Santos J.I., Marchi-Salvador D.P., Fernandes C.A.H., Silveira L.B., Soares A.M., and Fontes M.R.M. Preliminary X-ray crystallographic studies of a Lys49-phospholipase A2 homologue from Bothrops pirajai venom complexed with p-bromophenacyl bromide and α-tocopherol inhibitors. Protein Pept. Lett. 14 (2007) 698-701
26. Ebadi M., Srinivasan S.K., and Baxi M.D. Oxidative stress and anti-oxidant therapy in Parkinsońs disease. Prog. Neurobiol. 48 (1996) 1-19
27. Edgar R.C. MUSCLE: multiple sequence alignment with high accuracy and high throughput. Nucleic Acids Res. 32 (2004) 1792-1797
28. Francis B., Gutiérrez J.M., Lomonte B., and Kaiser I.I. Myotoxin II from Bothrops asper (Terciopelo) venom is a lysine-49 phospholipase A2. Arch. Biochem. Biophys. 284 (1991) 352-359
29. Gerrard J.M., and Robinson P. Increased phosphatidic acid and decreased lysophosphatidic acid in response to thrombin is associated with inhibition of platelet aggregation. Biochem. Cell Biol. 71 (1993) 432-439
30. Gijón M.A., and Leslie C.C. Regulation of arachidonic acid release and cytosolic phospholipase A2 activation. J. Leukoc. Biol. 65 (1999) 330-336
31. 2 myotoxins from Bothrops snake venoms. Toxicon 33 (1995) 1405-1424
32. 2 Enzymes. Structure, Function and Mechanism (1997), Wiley, New York 321-352
33. Gutiérrez J.M., Lomonte B., and Cerdas L. Isolation and partial characterization of a myotoxin from the venom of the snake Bothrops nummifer. Toxicon 24 (1986) 885-894
34. Jancarik J., and Kim S.H. Sparse matrix sampling: a screen method for crystallization of proteins. J. Appl. Crystallogr. 24 (1991) 409-411
35. Jones T.A., Bergdoll M., and Kjeldgaard M. O: a macromolecule modeling environment. In: Ealick S., and Bugg C.E. (Eds). Crystallographic and Modeling Methods in Molecular Design (1990), New York, Springer-Verlag 189-195
36. Krissinel E., and Henrick K. Inference of macromolecular assemblies from crystalline state. J. Mol. Biol. 372 (2007) 774-797
37. Laskowski R.A., MacArthur M.W., Moss D.S., and Thornton J.M. PROCHECK: a program to check the stereochemical quality of protein structures. J. Appl. Crytallogr. 26 (1993) 283-291
38. Lee W.H., da Silva-Giotto M.T., Marangoni S., Toyama M.H., Polikarpov I., and Garratt R.C. Structural basis for low catalytic activity in Lys49 phospholipases A2-a hypothesis: the crystal structure of piratoxin II complexed to fatty acid. Biochemistry 40 (2001) 28-36
39. Lloret S., and Moreno J.J. Oedema formation and degranulation of mast cells by phospholipase A2 purified from porcine pancreas and snake venoms. Toxicon 31 (1993) 949-956
40. 2 from Bothrops asper snake venom by glycosaminoglycans of the heparin/heparan sulfate family. Biochem. Pharmacol. 47 (1994) 1509-1518
41. Lomonte B., Angulo Y., and Calderón L. An overview of Lys49-phospholipase A2 myotoxins from crotalid snake venoms and their structural determinants of myotoxic action. Toxicon 42 (2003) 885-901
42. Lomonte B., Yamileth A., and Santamaría C. Comparative study of synthetic peptides corresponding to region 115-129 in Lys49 myotoxic phospholipases A2 from snake venoms. Toxicon 42 (2003) 307-312
43. MacPherson A. Preparation and Analysis of Protein Crystals (1982), Wiley, New York
44. Magro A.J., Soares A.M., Giglio J.R., and Fontes M.R.M. Crystal structures of BnSP-7 and BnSP-6, two Lys49-phospholipases A2: quaternary structure and inhibition mechanism insights. Biochem. Biophys. Res. Commun. 311 (2003) 713-720
45. Magro A.J., Murakami M.T., Marcussi S., Soares A.M., Arni R.K., and Fontes M.R.M. Crystal structure of an acidic platelet aggregation inhibitor and hypotensive phospholipase A2 in the monomeric and dimeric states: insights into its oligomeric state. Biochem. Biophys. Res. Comum. 323 (2004) 24-31
46. Mancuso L.C., Correa M.M., Vieira C.A., Cunha O.A.B., Lachatt J.J., Selistre-de-Araújo H.S., Owbny C.L., and Giglio J.R. Fractionation of Bothrops pirajai snake venom: isolation and characterization of piratoxin-I, a new myotoxic protein. Toxicon 33 (1995) 615-626
47. Marchi-Salvador D.P., Corrêa L.C., Magro A.J., Oliveira C.Z., Soares A.M., and Fontes M.R.M. Insights into the role of oligomeric state on the biological activities of crotoxin: crystal structure of a tetrameric phospholipase A(2) formed by two isoforms of crotoxin B from Crotalus durissus terrificus venom. Proteins 72 (2008) 883-891
48. Molenaar W.H., Kranenburg O., Postma F.R., and Zondag G.C.M. Lysophosphatidic acid: G-protein signalling and cellular responses. Curr. Opin. Cell Biol. 9 (1997) 168-173
49. Murakami M.T., Arruda E.Z., Melo P.A., Martinez A.B., Calil-Elias S., Tomaz M.A., Lomonte B., Gutiérrez J.M., and Arni R.K. Inhibition of myotoxic activity of Bothrops asper myotoxin II by the anti-trypanosomal drug suramin. J. Mol. Biol. 350 (2005) 416-426
50. Murakami M.T., Viçoti M.M., Abrego J.R.B., Lourenzoni M.R., Cintra A.C.O., Arruda E.Z., Tomaz M.A., Melo P.A., and Arni R.K. Interfacial surface charge and free accessibility to the PLA2-active site-like region are essential requirements for the activity of Lys49 PLA2 homologues. Toxicon 49 (2007) 378-387
51. Navaza J. AMoRe: an automated package for molecular replacement. Acta Crystallogr. A 50 (1994) 157-163
52. Needleman P., Turk J., Jakschik B.A., Morrison A.R., and Lefkowith J.B. Arachidonic acid metabolism. Annu. Rev. Biochem. 55 (1986) 69-102
53. Núnez C.E., Yamileth A., and Lomonte B. identification of the myotoxic site of the Lys49 phospholipase A2 rom Agkistrodon piscivorus piscivorus snake venom: synthetic C-terminal peptides from Lys49, but not from Asp49 myotoxins, exert membrane-damaging activities. Toxicon 39 (2001) 1587-1594
54. Otwinowski Z., and Minor W. Processing of X-ray diffraction data collected in oscillation mode. Methods Enzymol. 276 (1997) 307-326
55. Paramo L., Lomonte B., Pizarro-Cerda J., Bengoechea J.A., Gorvel J.P., and Moreno E. Bactericidal activity of Lys49 and Asp49 myotoxic phospholipases A2 from Bothrops asper snake venom-synthetic Lys49 myotoxin II-(115-129)-peptide identifies its bactericidal region. Eur. J. Biochem. 253 (1998) 452-461
56. Pentland A.P., Morrison A.R., Jacobs S.C., Hruza L.L., Hebert J.S., and Packer L. Tocopherol analogues suppress arachidonic acid metabolism via phospholipase inhibition. J. Biol. Chem. 267 (1992) 1603-1608
57. Rosenberg P. Phospholipases. In: Shier W.T., and Mebs D. (Eds). Handbook of Toxinology (1990), New York, Marcel Dekker 67-277
58. Sano M., Ernesto C., Thomas R.G., Klauber M.R., Schafer K., Grundman M., Woodbury P., Gowdon J., Cotman C.W., Pfeiffer E., Schneider L.S., and Thal L.J. A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study. N. Engl. J. Med. 336 (1997) 1216-1222
59. 2 from the venom of Agkistrodon piscivorus piscivorus. J. Biol. Chem. 267 (1992) 22645-22657
60. Simons K., and Toomre D. Lipid rafts and signal transduction. Nat. Rev. Mol. Cell Biol. 1 (2000) 31-39
61. Soares A.M., and Giglio J.R. Chemical modifications of phospholipases A2 from snake venoms: effects on catalytic and pharmacological properties. Toxicon 42 (2003) 855-868
62. 2 homologue, from Bothrops neuwiedi pauloensis venom. Arch. Biochem. Biophys. 378 (2000) 201-209
63. 2 from Bothrops pirajai snake venom. Arch. Biochem. Biophys. 387 (2001) 188-196
64. 2 subunit of crotoxin from Crotalus durissus terrificus snake venom, on its enzymatic and pharmacological activities. Int. J. Biochem. Cell Biol. 33 (2001) 877-888
65. Soares A.M., Fontes M.R.M., and Giglio J.R. Phospholipase A2 myotoxins from Bothrops snake venoms: structure function relationship. Curr. Org. Chem. 8 (2004) 1677-1690
66. Takeda A.A.S., dos Santos J.I., Marchi-Salvador D.P., Soares A.M., and Fontes M.R.M. Crystallization and preliminary X-ray crystallographic studies of a myotoxic Lys49-phospholipase A2 from Bothrops jararacussu venom complexed with α-tocopherol inhibitor. Open Crystallogr. J. 1 (2008) 6-9
67. Toyama M.H., Soares A.M., Vieira C.A., Novello J.C., Oliveira B., Giglio J.R., and Marangoni S. Amino acid sequence of piratoxin-I, a myotoxin from Bothrops pirajai snake venom, and its biological activity after alkylation with p-bromophenacyl bromide. J. Protein Chem. 17 (1998) 713-718
68. van Deenen L.L.M., and de Haas G.H. The substrate specificity of phospholipase A2. Biochem. Biophys. Acta 70 (1963) 538-553
69. Wallace A.C., Laskowski R.A., and Thornton J.M. LIGPLOT: a program to generate schematic diagrams of protein-ligand interactions. Prot. Eng. 8 (1995) 127-134
70. Ward R.J., Rodrigues Alves A., Ruggiero Neto J., Arni R.K., and Casari G. A sequence space analysis of phospholipase A2. Protein Eng. 11 (1998) 285-294
71. Ward R.J., Chioato L., de Oliveira A.H.C., Ruller R., and Sá J.M. Active-site mutagenesis of a Lys49-phospholipase A2: biological and membrane-disrupting activities in the absence of catalysis. Biochem. J. 362 (2002) 89-96
72. Watanabe L., Soares A.M., Ward R.J., Fontes M.R.M., and Arni R.K. Structural insights for fatty acid binding in a Lys49-phospholipaseA2: crystal structure of myotoxin II from Bothrops moojeni complexed with stearic acid. Biochimie 87 (2005) 161-167